Table 1 Inclusion and exclusion criteria

· Must be 18 years of age or older

· Diagnosed with Type 1 or Type 2 diabetes

· Recent HbA1c #62;7.5% (measured within the last 6 weeks at local laboratory)

· Using MDI therapy for at least 6 months consisting of 1–2 injections per day of long-acting basal insulin (Lantus® or Detemir®) and at least 2 injections per day of regular or rapid-acting analog insulin for meal coverage

· Participant adjusts meal insulin doses based on carbohydrate content of meals

· Participant with Type 2 diabetes may be on stable metformin therapy (therapy unchanged during 3 months prior to study)

· Participant has been in Investigator's practice for at least 3 months; however may have been seen by another physician in the practice

· Participant has completed carbohydrate (CHO) training within the last 2 years

Exclusion Criteria:

· On a therapy regimen that conflicts with study:

· NPH or pre-mixed insulin

· Oral anti-diabetic agents, with the exception of metformin

· Injectable anti-diabetic agents other than long-acting insulin and rapid-acting insulin analogs or regular insulin (e.g., fixed dose therapy)

· Use of sliding scale insulin therapy that determines insulin dosages based exclusively on specific bG results

· Participated in another interventional trial within 6 weeks prior to study

· Diagnosed with any clinically significant infectious disease or major organ system disease, such as gastroparesis or renal disease (at Investigator's discretion)

· Used systemic oral or inhaled steroids for more than 7 days within the last 3 months

· On Chemotherapy or Radiation therapy (self-reported)

· Pregnant or lactating or is currently planning a pregnancy